Literature DB >> 12928908

Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome.

Masaaki Odaka1, Nobuhiro Yuki, Koichi Hirata.   

Abstract

Progression periods for Guillain-Barré syndrome (GBS) differ from those of chronic inflammatory demyelinating polyneuropathy (CIDP), but physicians could classify patients with CIDP within 4 weeks of onset as GBS. We studied and report the frequency of GBS patients who were later diagnosed as CIDP (11/663, 2%). Plasmapheresis or intravenous immunoglobulin transiently improved all the 11 patients, who 11 progressed slowly or had a relapse beyond the 8 weeks, and the other 2 suffered a relapse between 4 and 8 weeks from the onset. Three patients had had an antecedent infectious illness. CSF albumino-cytological dissociation was detected in 6 patients within 2 weeks of onset. Recognition of the existence of such patients is important for the early diagnosis and treatment of those patients with CIDP for whom GBS has been diagnosed at onset.

Entities:  

Mesh:

Year:  2003        PMID: 12928908     DOI: 10.1007/s00415-003-1096-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  10 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 2.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

3.  The Diagnostic, Prognostic, and differential value of enhanced MR imaging in Guillain-Barre syndrome.

Authors:  H-F Li; X-J Ji
Journal:  AJNR Am J Neuroradiol       Date:  2011-05-19       Impact factor: 3.825

4.  Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy.

Authors:  Jia-Ying Sung; Jowy Tani; Susanna B Park; Matthew C Kiernan; Cindy Shin-Yi Lin
Journal:  Brain       Date:  2014-06-19       Impact factor: 13.501

5.  Biomarkers of 'acute-onset' chronic inflammatory demyelinating polyneuropathy.

Authors:  Yumako Miura; Nortina Shahrizaila; Nobuhiro Yuki
Journal:  Brain       Date:  2014-09-02       Impact factor: 13.501

Review 6.  Association between chronic inflammatory demyelinating polyneuropathy and gastrointestinal malignancies.

Authors:  Adnan Malik; Rani Berry; Brian M Fung; James H Tabibian
Journal:  Clin J Gastroenterol       Date:  2020-11-04

Review 7.  Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Authors:  Emily K Mathey; Susanna B Park; Richard A C Hughes; John D Pollard; Patricia J Armati; Michael H Barnett; Bruce V Taylor; P James B Dyck; Matthew C Kiernan; Cindy S-Y Lin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-12       Impact factor: 10.154

8.  Pyrexia-associated Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Authors:  Jun Ueda; Hajime Yoshimura; Nobuo Kohara
Journal:  Intern Med       Date:  2018-04-27       Impact factor: 1.271

Review 9.  Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.

Authors:  Paolo Ripellino; Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Autoimmune Dis       Date:  2014-01-14

10.  Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report.

Authors:  Jong Youb Lim; Young-Ho Lim; Eun-Hi Choi
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.